Researchers from Microgen developed the universal capsule bacteriophage

| By | Drug Development, Microgen

NPO Microgen of Nacimbio, a part of Rostec Corporation, has developed a universal medicinal product that allows to take just one capsule instead of the entire set of traditional antimicrobial agents against infectious diseases.

The drug targets only bacterial cells without affecting normal body flora. It represents a capsule for oral administration containing a specialized complex of dry bacteriophages that can combat  diseases caused simultaneously by several pathogens. This eliminates the need to use a set of medicines for separate treatment and prevention of each disease.

“There is no other similar product in the world, where just one capsule includes an antimicrobial complex of bacteriophages to prevent and combat a wide range of common bacterial infections. The drug has already been created and will be released to market after completion of required studies and state registration. At this point, it has successfully passed preclinical studies and phase I clinical trials, which demonstrated its safety,” said Kirill Gaidash, General Director of NPO Microgen.

New product of Rostec will allow treatment and prevention of the diseases caused by genus Staphylococcus, Streptococcus, Proteus vulgaris and Proteus mirabilis, Klebsiella pneumoniae, as well as Pseudomonas aeruginosa and Escherichia coli.